Literature DB >> 5801345

Effects of chlorpromazine in patients with hepatic disease.

A E Read, J Laidlaw, C F McCarthy.   

Abstract

Patients with cirrhosis were found to be extremely sensitive to chlorpromazine as shown by slowing of the electroencephalograph (E.E.G.), which was particularly definite in those who had had hepatic encephalopathy previously. Patients showing the most definite E.E.G. changes were in general very sleepy and took some hours to recover after taking chlorpromazine. It is concluded that phenothiazine drugs should be used very cautiously in patients with alcoholic liver disease.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5801345      PMCID: PMC1984315          DOI: 10.1136/bmj.3.5669.497

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  8 in total

1.  Neuropsychiatric complications of portacaval anastomosis.

Authors:  A E READ; J LAIDLAW; S SHERLOCK
Journal:  Lancet       Date:  1961-05-06       Impact factor: 79.321

2.  Morphine tolerance in hepatic cirrhosis.

Authors:  J LAIDLAW; A E READ; S SHERLOCK
Journal:  Gastroenterology       Date:  1961-03       Impact factor: 22.682

3.  Neuropsychiatric complications following chlorothiazide therapy in patients with hepatic cirrhosis: possible relation to hypokalaemia.

Authors:  A E READ; J LAIDLAW; R M HASLAM; S SHERLOCK
Journal:  Clin Sci       Date:  1959-08       Impact factor: 6.124

4.  The measurement of ammonia in whole blood, erythrocytes, and plasma.

Authors:  D SELIGSON; K HIRAHARA
Journal:  J Lab Clin Med       Date:  1957-06

5.  Observations of liver function in chlorpromazine-treated alcoholic patients.

Authors:  M D SMALL; A E LONGARINI; N ZAMCHECK
Journal:  N Engl J Med       Date:  1957-05-16       Impact factor: 91.245

6.  Treatment of the acute alcohol-withdrawal syndrome.

Authors:  L GODFREY; M D KISSEN; T M DOWNS
Journal:  Q J Stud Alcohol       Date:  1958-03

7.  Delirium tremens; reduction of mortality and morbidity with promazine.

Authors:  F A FIGURELLI
Journal:  J Am Med Assoc       Date:  1958-02-15

8.  The colorimetric estimation of 3-chlorpromazine in biological fluids.

Authors:  H LEACH; W R CRIMMIN
Journal:  J Clin Pathol       Date:  1956-05       Impact factor: 3.411

  8 in total
  14 in total

1.  Sedation in liver disease.

Authors: 
Journal:  Br Med J       Date:  1977-05-14

Review 2.  Some clinical features of liver cell failure: an appraisal of their causes.

Authors:  A E Read
Journal:  Gut       Date:  1978-06       Impact factor: 23.059

3.  Medium chain triglycerides and hepatic encephalopathy.

Authors:  M H Morgan; C H Bolton; J S Morris; A E Read
Journal:  Gut       Date:  1974-03       Impact factor: 23.059

4.  Clinical and electroencephalographic assessment of diazepam in liver disease.

Authors:  I M Murray-Lyon; J Young; J D Parkes; R P Knill-Jones; R Williams
Journal:  Br Med J       Date:  1971-10-30

5.  Treatment of fulminant hepatic failure. Clinical syndrome and basis of therapy.

Authors:  R Williams
Journal:  Br Med J       Date:  1971-01-23

Review 6.  Clinical pharmacokinetics of the depot antipsychotics.

Authors:  M W Jann; L Ereshefsky; S R Saklad
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

7.  Neuropsychologic effects of diazepam related to single dose kinetics and liver function.

Authors:  J Hendel; P Elsass; P B Andreasen; E Gymoese; E F Hvidberg
Journal:  Psychopharmacology (Berl)       Date:  1976-07-09       Impact factor: 4.530

Review 8.  Drug prescribing in hepatobiliary disease.

Authors:  R K Roberts; P V Desmond; S Schenker
Journal:  Drugs       Date:  1979-03       Impact factor: 9.546

Review 9.  Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation.

Authors:  Chantal Schlatter; Sabin S Egger; Lydia Tchambaz; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

10.  Plasma concentrations and central nervous system effects of the new hypnotic agent zopiclone in patients with chronic liver disease.

Authors:  G Parker; C J Roberts
Journal:  Br J Clin Pharmacol       Date:  1983-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.